TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
Ahead of Q4 2025 earnings, the firm adjusted price targets within the diagnostic tools group and noted that investor sentiment is beginning to shift positively. 2026 guidance will be key for investors looking to position themselves for a sector-wide recovery. On the same day, Takeda and Halozyme Therapeutics announced a global collaboration and exclusive license agreement. The partnership grants Takeda exclusive access to Halozyme's proprietary ENHANZE drug-delivery technology for use with vedolizumab, which is marketed globally as ENTYVIO. Vedolizumab is a biologic therapy approved for treating adults with moderately to severely active ulcerative colitis and Crohn's disease, with total global exposure surpassing one million patient years to date. The agreement was finalized in December 2025 and provides Takeda with Halozyme Therapeutics Inc.'s (NASDAQ:HALO) recombinant human hyaluronidase PH20 enzyme to facilitate the subcutaneous delivery of vedolizumab. By integrating this comm
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..MarketBeat
- Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth [Seeking Alpha]Seeking Alpha
- What Halozyme Therapeutics (HALO)'s Upgraded Revenue Outlook and ENHANZE Acquisitions Strategy Means For Shareholders [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
HALO
Earnings
- 11/3/25 - Beat
HALO
Sec Filings
- 2/5/26 - Form 4
- 2/3/26 - Form 144
- 1/28/26 - Form 8-K
- HALO's page on the SEC website